HEK293 Human TRPV6 Stable Cell

HEK293 Human TRPV6 Stable Cell

Item	Cat#	Price
Stable Cell Line	SNB-I-0010A	$19,800
Compound Test Services	CT-001	$1,850 per 384w plate *(Up To 16 cpds Dose)*

Ask For A Custom Quote

Product Description

Transient Receptor Potential Vanilloid subtype 6 (TRPV6) channels are a diverse family of non-selective cation channels involved in sensing a wide range of physical and chemical stimuli, including temperature, mechanical forces, pH, and ligands such as capsaicin and menthol. They are broadly expressed in sensory neurons and other tissues, playing essential roles in pain perception, thermoregulation, inflammation, and cellular homeostasis. The TRP channel family is divided into several subfamilies, including TRPC, TRPV, TRPM, TRPA, TRPP, and TRPML, each with distinct physiological functions and activation mechanisms. Due to their central role in sensory signaling and disease, TRP channels are emerging as promising therapeutic targets for pain, inflammation, and various neurological and cardiovascular disorders.

Screeningbio’s TRPV6 cell line stable express non-tag full length human TRPV6 receptor in HEK293 cell. When activated, TRPV6 cell line response to extracellular stimuli and result in channel opening and calcium influx. Increase of intercellular calcium was detected by calcium sensitive dye.

Product Specifications

Target Type	Ion Channel
Species	Human
HGNC Symbol	TRPV6
Accession Number	NM_018646
Parental Line	HEK293
Lot#	See Vial
Storage	Liquid Nitrogen

Data

Human TRPV6 Blocker Assay. HEK293 Human TRPV6 cells were seeded in 384-well plate and incubated at 37oC in 5% CO2 incubator for 24 hours before running the assay. The cells were treated with the reference blockers, and stimulated by activator. The assay was run based on FLIPR Calcium assay protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 /IC50 values were determined, using GraphPad Prism software. — **Human TRPV6 Blocker Assay.** HEK293 Human TRPV6 cells were seeded in 384-well plate and incubated at 37^oC in 5% CO₂ incubator for 24 hours before running the assay. The cells were treated with the reference blockers, and stimulated by activator. The assay was run based on FLIPR Calcium assay protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 /IC50 values were determined, using GraphPad Prism software.

Target Background

The transient receptor potential vanilloid 6 (TRPV6) is a highly calcium-selective member of the TRP channel superfamily and plays a critical role in epithelial calcium absorption and systemic calcium homeostasis. Unlike most other TRPV family members that respond to physical or chemical stimuli, TRPV6 functions primarily as a constitutively active calcium entry channel regulated by hormonal and cellular signaling pathways. It is predominantly expressed in calcium-transporting epithelia such as the intestine, placenta, prostate, and exocrine glands, where it mediates transcellular calcium uptake essential for physiological processes including bone mineralization, lactation, and reproductive function.

At the molecular level, TRPV6 allows calcium influx across the apical membrane of epithelial cells, which is then coupled to intracellular calcium-binding proteins (e.g., calbindin-D9k) and extrusion mechanisms (PMCA1b and NCX1) to maintain calcium balance. Its expression and activity are tightly controlled by vitamin D, estrogen, and other endocrine factors, reflecting its central role in calcium metabolism.

Dysregulation of TRPV6 has been associated with several pathological conditions, including calcium absorption disorders, infertility, and various cancers such as prostate, breast, and colon cancer, where it contributes to enhanced proliferation and survival of tumor cells. Due to its high calcium selectivity and restricted tissue distribution, TRPV6 represents an attractive therapeutic target for managing calcium-related metabolic diseases and malignancies.